CIK 0001823239 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 185.7 M | 883.0 M | ||
| Net income (USD) | 89.0 M | -4.5 M | ||
| Diluted EPS (USD/shares) | -0.9 | 1.67 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-09 | 4 | FORM 4 | 2026-10-08 |
| 2026-10-01 | 4 | FORM 4 | 2026-09-30 |
| 2026-09-29 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-09 | 4 | FORM 4 | 2026-09-08 |
| 2026-09-01 | 4 | FORM 4 | 2026-08-31 |
| 2026-08-13 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | 4 | FORM 4 | 2026-08-10 |
| 2026-08-07 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-08-03 | 4 | FORM 4 | 2026-07-30 |
| 2026-07-10 | 4 | FORM 4 | 2026-07-08 |
| 2026-07-01 | 4 | FORM 4 | 2026-06-30 |
| 2026-06-29 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-23 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-10 | 4 | FORM 4 | 2026-06-08 |
| 2026-06-10 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-10 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-10 | 144 | 144 | |
| 2026-06-09 | 144 | 144 | |
| 2026-06-03 | 8-K | 8-K items 1.01,1.02,2.03,7.01,9.01 | 2026-06-02 |
| 2026-05-29 | 8-K | 8-K items 5.07 | 2026-05-26 |
| 2026-05-28 | 4/A | FORM 4/A | 2026-05-26 |
| 2026-05-28 | 4 | FORM 4 | 2026-05-26 |
| 2026-05-28 | 4 | FORM 4 | 2026-05-26 |
| 2026-05-28 | 4 | FORM 4 | 2026-05-26 |
Forms on file (last 1,000): 4 193, 8-K 55, 3 26, SC 13G/A 22, 10-Q 17, CORRESP 13, SC 13G 13, UPLOAD 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MRVI (0.002 USD), /gw/filings/filings?ticker=MRVI&form=8-K, /gw/filings/facts?ticker=MRVI&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange